Large Molecule Drug Substance CDMO Market Size, Share, Growth Analysis, By Service(Contract manufacturing and contract development), By Source(Microbial, mammalian, and other), By Region - Industry Forecast 2024-2031

Large Molecule Drug Substance CDMO Market Drivers

Increasing Biologics and Biosimilars Research and Development

• Numerous companies have made large expenditures in the development of biologics and biosimilar substances since the epidemic. Currently, about half of the potential therapeutic candidates are biologics at the discovery stage, such as peptides, proteins, and monoclonal antibodies. Numerous innovative biologics are either being developed or are in the pipeline as a result of the increased investment in research and development by biopharmaceutical companies. Therefore, each of these reasons contributes to the expansion of the market for CDMOs for large molecular drugs.

Expanding Cardiovascular Diseases (CVD) and Deaths due to CVD

• The number of individuals who die from cardiovascular disease (CVD) is constantly rising, according to a report that analyzed the overall severity of CVD burden and was published in the Journal of the American College of Cardiology. Additionally, one-third of all fatalities worldwide in 2019 are included in this total. The figures demonstrate the urgent need for countries to establish cost-effective public health programs that are aimed at reducing the risk of heart disease through modifiable habits.

Large Molecule Drug Substance CDMO Market Restraints

Strict Parameters and Regulations, Complex Analytical Characterization of Biologics

• Large molecules are particularly difficult to characterize. Characterization in the biopharmaceutical industry is required in a variety of contexts, such as stability, purity, and function. For effective structural validation of large molecules, a variety of low- and high-resolution approaches must be combined. Additionally, the recombinant synthesis approach results in the production of multiple post-translational modifications (PTMs) by big molecules. Therefore, the growth and development of the large molecule drug substance CDMO market are being aided by the increase in R&D and product development spending.